New potential drug evaluation in cholestatic pruritus

Recruting new patients

Select region:

Navigation:

    What is this study about?

    This study aims to assess the effectiveness of the potential new drug-EP547 in alleviating cholestatic pruritus among individuals aged 18 to 80 with Primary Biliary Cholangitis (PBC) or Primary Sclerosing Cholangitis (PSC). Inclusion criteria involve documented diagnoses of PBC or PSC, the presence of moderate to severe pruritus, and acceptance of specific anti-pruritic and anti-cholestatic medications. Exclusion criteria include pruritus unrelated to PBC or PSC, a history of liver transplantation, cirrhosis, alternative liver diseases, secondary sclerosing cholangitis, significant strictures or biliary stents, small bowel resection, and certain laboratory results indicating ineligibility.

    Learn more about this Trial

      I accept the Terms of Use and Privacy Policy*

       I consent to the Service Operator sending commercial information*

      I consent to the Service Operator using telecommunications terminal devices and automatic calling systems in marketing communications*

      Success

      Your form submitted successfully!

      Error

      Sorry! your form was not submitted properly, Please check the errors above.

      Locations

      Where does the clinical trial take place?

      Antwerpen , Belgium

      Gent , Belgium

      Leuven , Belgium

      Bobigny , France

      Grenoble , France

      Lille , France

      Paris , France

      Toulouse , France

      Villejuif , France

      Amsterdam , Netherlands

      Alicante , Spain

      Barcelona , Spain

      Pontevedra , Spain

      Sevilla , Spain

      Valencia , Spain

      Zaragoza , Spain

      Birmingham , United Kingdom

      Glasgow , United Kingdom

      London , United Kingdom

      Newcastle , United Kingdom

      Norwich , United Kingdom

      Nottingham , United Kingdom

      Plymouth , United Kingdom

      You can join this study in:

      Study Steps

      How Complex Will My Study Be and What Phases Will I Go Through?

      Based on the information provided about this clinical trial, here are the key steps a patient would likely need to take if participating:

      1. Screening: The patient would be evaluated against the inclusion/exclusion criteria to determine if they are eligible to participate. This includes being 18-80 years old, having documented PBC or PSC, and having consistent moderate to severe pruritus (itching).
      2. Randomization: If deemed eligible after screening, the patient would be randomly assigned to receive either the investigational drug EP547 (100mg once daily) or a placebo for comparison.
      3. Treatment Period: The patient would take their assigned treatment (EP547 or placebo) once daily for 6 weeks. During this time:
        • Pruritus intensity would be measured using the Worst Itch Numeric Rating Scale (WI-NRS) and other itch questionnaires
        • Safety would be monitored by tracking any adverse events
        • Blood samples would likely be collected to measure EP547 levels for pharmacokinetic analysis
      4. End of Treatment: After the 6 week treatment period, a final evaluation would be done to assess the patient’s pruritus and compare to baseline scores to determine if the drug had an effect. This would mark the end of the patient’s active participation.

      In summary, the key commitment for a patient would be taking a daily oral medication for 6 weeks and attending any required study clinic visits for assessments and blood draws over that period. The entire process from screening to end of treatment looks to last about 6-8 weeks total.


      Diseases Under Investigation

      What Conditions Qualify Me for This Study?

      Based on the eligibility criteria in the provided clinical trial information, to join this study you need to have one of the following diseases:

      • Documented primary biliary cholangitis (PBC), or
      • Documented primary sclerosing cholangitis (PSC)

      You would not be eligible if you have:

      • Pruritus (itching) associated with a cause other than PBC or PSC
      • Evidence of compensated or decompensated cirrhosis
      • Alternative causes of liver disease
      • Documented secondary sclerosing cholangitis

      Terms and conditions

      What Requirements I Have to Meet To Join This Study?

      When Am I Eligible to Join the Study?

      To join this clinical trial, you must meet the following criteria:

      Inclusion Criteria:

      • Age 18 to 80 years old
      • Documented primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC)
        • PBC and PSC are both chronic liver diseases that cause inflammation and scarring of the bile ducts
      • Presence of consistent moderate to severe pruritus (itching)
      • Use of anti-pruritic (anti-itch) and anti-cholestatic (bile flow improving) medication is allowed, including:
        • Ursodeoxycholic acid (UDCA)
        • Obeticholic acid

        As long as you meet additional criteria

      • If you have concomitant inflammatory bowel disease (IBD), which commonly occurs alongside PSC, you must meet additional relevant criteria

      The trial does not mention any specific indexes or scales in the inclusion criteria that require further explanation.

      In summary, the main conditions are being 18-80 years old, having documented PBC or PSC, experiencing consistent moderate to severe itching, and being allowed to continue certain medications for itching and bile flow. Additional criteria apply for those with IBD.

      What Reasons Could Exclude Me from the Study?

      Based on the eligibility criteria, you cannot take part in the study if you have any of the following:

      Other causes of pruritus (itching):
      If your pruritus is due to a cause other than primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC), you are not eligible. PBC and PSC are chronic liver diseases that can cause itching.

      Previous or planned liver transplant:
      If you have had a liver transplant in the past or are planning to have one, you cannot participate.

      Cirrhosis:
      Cirrhosis is severe scarring of the liver. If you have either compensated cirrhosis (milder form) or decompensated cirrhosis (more advanced form with complications), you are excluded.

      Other liver diseases:
      If you have other causes of liver disease besides PBC or PSC, you cannot take part.

      Secondary sclerosing cholangitis:
      This is a type of liver disease similar to PSC but caused by a known separate condition. If you have documented secondary sclerosing cholangitis, you are not eligible.

      Severe bile duct narrowing or stents:
      If you currently have significant narrowing (strictures) of the bile ducts or have a biliary stent in place, you cannot participate.

      Bowel surgery:
      If you have a history of major small intestine resection surgery or short bowel syndrome, you are excluded.

      Abnormal lab results:
      Certain abnormal laboratory or biochemical results at the screening visit will prevent you from participating.


      Investigational Medicinal Product

      What Products Are Being Used in This Study?

      The drugs involved in this study are:

      1. EP547 (active substance unknown): This is the investigational drug being evaluated for its effects on cholestatic pruritus in patients with Primary Biliary Cholangitis (PBC) or Primary Sclerosing Cholangitis (PSC). EP547 is administered once daily in the treatment arm of the study.
      2. Placebo: A placebo is a substance with no active therapeutic effect, used as a control in the study to compare against the investigational drug EP547. It is administered once daily in the placebo arm of the study.

      The study is designed to evaluate the efficacy and safety of EP547 in reducing pruritus (itching) in patients with PBC or PSC. Participants are randomly assigned to receive either EP547 or placebo for 6 weeks, and the severity of their pruritus is measured using various scales and questionnaires. The use of a placebo helps determine if any observed improvements are due to the active drug or other factors.

      Have the Medicinal Substances Used in the Trial Been Previously Studied in Medicine?

      Based on the information provided in the clinical trial record, the active substances being studied are:

      1. EP547
        • EP547 appears to be an investigational drug being developed by Escient Pharmaceuticals. As an investigational therapy, it is likely a novel compound that is not yet well established in medical literature or approved as a treatment.
      2. Placebo
        • Placebos are inactive substances used as a control in clinical trials. They are well known and widely used in medical research to help determine the effectiveness of the investigational treatment.

      Study ID

      CT-EU-00057508

      Recruitment status

      Recruting new patients

      Start of the trial

      2 years ago

      Study phase

      Phase
      II

      Diseases